KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

KJ Harrington; D Rischin; Richard Greil; D Soulieres; M Tahara; G Castro; A Psyrri; N Baste; PC Neupane; A Bratland; T Fuereder; BGM Hughes; R Mesia; N Ngamphaiboon; T Rordorf; WZW Ishak; YY Zhang; B Gumuscu; RF Swaby; B Burtness

KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

KJ Harrington, D Rischin, Richard Greil, D Soulieres, M Tahara, G Castro, A Psyrri, N Baste, PC Neupane, A Bratland, T Fuereder, BGM Hughes, R Mesia, N Ngamphaiboon, T Rordorf, WZW Ishak, YY Zhang, B Gumuscu, RF Swaby, B Burtness

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

18 Citations (Web of Science)

Original language	English
Journal	JOURNAL OF CLINICAL ONCOLOGY
Volume	38
Issue number	15
Publication status	Published - 2020

Cite this

Harrington, KJ., Rischin, D., Greil, R., Soulieres, D., Tahara, M., Castro, G., Psyrri, A., Baste, N., Neupane, PC., Bratland, A., Fuereder, T., Hughes, BGM., Mesia, R., Ngamphaiboon, N., Rordorf, T., Ishak, WZW., Zhang, YY., Gumuscu, B., Swaby, RF., & Burtness, B. (2020). KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). JOURNAL OF CLINICAL ONCOLOGY , 38(15).

Harrington, KJ ; Rischin, D ; Greil, Richard et al. / KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). In: JOURNAL OF CLINICAL ONCOLOGY 2020 ; Vol. 38, No. 15.

@article{27388f4c1e2d400b9c9d25db20a2e02f,

title = "KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).",

author = "KJ Harrington and D Rischin and Richard Greil and D Soulieres and M Tahara and G Castro and A Psyrri and N Baste and PC Neupane and A Bratland and T Fuereder and BGM Hughes and R Mesia and N Ngamphaiboon and T Rordorf and WZW Ishak and YY Zhang and B Gumuscu and RF Swaby and B Burtness",

year = "2020",

language = "English",

volume = "38",

journal = "JOURNAL OF CLINICAL ONCOLOGY ",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins ",

number = "15",

}

Harrington, KJ, Rischin, D, Greil, R, Soulieres, D, Tahara, M, Castro, G, Psyrri, A, Baste, N, Neupane, PC, Bratland, A, Fuereder, T, Hughes, BGM, Mesia, R, Ngamphaiboon, N, Rordorf, T, Ishak, WZW, Zhang, YY, Gumuscu, B, Swaby, RF & Burtness, B 2020, 'KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).', JOURNAL OF CLINICAL ONCOLOGY , vol. 38, no. 15.

KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). / Harrington, KJ; Rischin, D; Greil, Richard et al.
In: JOURNAL OF CLINICAL ONCOLOGY , Vol. 38, No. 15, 2020.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

AU - Harrington, KJ

AU - Rischin, D

AU - Greil, Richard

AU - Soulieres, D

AU - Tahara, M

AU - Castro, G

AU - Psyrri, A

AU - Baste, N

AU - Neupane, PC

AU - Bratland, A

AU - Fuereder, T

AU - Hughes, BGM

AU - Mesia, R

AU - Ngamphaiboon, N

AU - Rordorf, T

AU - Ishak, WZW

AU - Zhang, YY

AU - Gumuscu, B

AU - Swaby, RF

AU - Burtness, B

PY - 2020

Y1 - 2020

M3 - Abstract (Journal)

SN - 0732-183X

VL - 38

JO - JOURNAL OF CLINICAL ONCOLOGY

JF - JOURNAL OF CLINICAL ONCOLOGY

IS - 15

ER -

Harrington KJ, Rischin D, Greil R, Soulieres D, Tahara M, Castro G et al. KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). JOURNAL OF CLINICAL ONCOLOGY . 2020;38(15).